Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement.

Tiede A, Giangrande P, Teitel J, Amano K, Benson G, Nemes L, Jiménez-Yuste V, d'Oiron R, Benchikh El Fegoun S, Kessler CM.

Haemophilia. 2019 Nov;25(6):969-978. doi: 10.1111/hae.13844. Epub 2019 Sep 13.

PMID:
31517435
2.

An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.

Veeramani S, Blackwell SE, Thiel WH, Yang ZZ, Ansell SM, Giangrande PH, Weiner GJ.

Cancer Immunol Res. 2019 Sep;7(9):1511-1522. doi: 10.1158/2326-6066.CIR-18-0821. Epub 2019 Aug 5.

PMID:
31383650
3.

mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency.

Cao J, An D, Galduroz M, Zhuo J, Liang S, Eybye M, Frassetto A, Kuroda E, Funahashi A, Santana J, Mihai C, Benenato KE, Kumarasinghe ES, Sabnis S, Salerno T, Coughlan K, Miracco EJ, Levy B, Besin G, Schultz J, Lukacs C, Guey L, Finn P, Furukawa T, Giangrande PH, Saheki T, Martini PGV.

Mol Ther. 2019 Jul 3;27(7):1242-1251. doi: 10.1016/j.ymthe.2019.04.017. Epub 2019 Apr 23.

PMID:
31056400
4.

Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter.

Udofot O, Lin LH, Thiel WH, Erwin M, Turner E, Miller FJ Jr, Giangrande PH, Yazdani SK.

Mol Ther Nucleic Acids. 2019 Jun 7;16:360-366. doi: 10.1016/j.omtn.2019.03.005. Epub 2019 Mar 23.

5.

RNA inhibitors of nuclear proteins responsible for multiple organ dysfunction syndrome.

Urak KT, Blanco GN, Shubham S, Lin LH, Dassie JP, Thiel WH, Chen Y, Sonkar VK, Lei B, Murthy S, Gutierrez WR, Wilson ME, Stiber JA, Klesney-Tait J, Dayal S, Miller FJ Jr, Giangrande PH.

Nat Commun. 2019 Jan 10;10(1):116. doi: 10.1038/s41467-018-08030-y.

6.

Aptamers as Diagnostic Tools in Cancer.

Ruiz Ciancio D, Vargas MR, Thiel WH, Bruno MA, Giangrande PH, Mestre MB.

Pharmaceuticals (Basel). 2018 Sep 11;11(3). pii: E86. doi: 10.3390/ph11030086. Review.

7.

European principles of inhibitor management in patients with haemophilia.

Giangrande PLF, Hermans C, O'Mahony B, de Kleijn P, Bedford M, Batorova A, Blatný J, Jansone K; European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD).

Orphanet J Rare Dis. 2018 Apr 27;13(1):66. doi: 10.1186/s13023-018-0800-z. Review.

8.

EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.

Garcia-Monclús S, López-Alemany R, Almacellas-Rabaiget O, Herrero-Martín D, Huertas-Martinez J, Lagares-Tena L, Alba-Pavón P, Hontecillas-Prieto L, Mora J, de Álava E, Rello-Varona S, Giangrande PH, Tirado OM.

Int J Cancer. 2018 Sep 1;143(5):1188-1201. doi: 10.1002/ijc.31405. Epub 2018 Apr 16.

9.

Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology.

Kruspe S, Dickey DD, Urak KT, Blanco GN, Miller MJ, Clark KC, Burghardt E, Gutierrez WR, Phadke SD, Kamboj S, Ginader T, Smith BJ, Grimm SK, Schappet J, Ozer H, Thomas A, McNamara JO 2nd, Chan CH, Giangrande PH.

Mol Ther Nucleic Acids. 2017 Sep 15;8:542-557. doi: 10.1016/j.omtn.2017.08.004. Epub 2017 Aug 12.

10.

Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.

Kruspe S, Giangrande PH.

Biomedicines. 2017 Aug 9;5(3). pii: E45. doi: 10.3390/biomedicines5030045. Review.

11.

Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices.

Neufeld EJ, Solimeno L, Quon D, Walsh C, Seremetis S, Cooper D, Iyer NN, Hoxer CS, Giangrande P.

Haemophilia. 2017 Nov;23(6):821-831. doi: 10.1111/hae.13279. Epub 2017 Jul 27. Review.

PMID:
28752639
12.

Design and Preparation of Aptamer-siRNA Chimeras (AsiCs) for Targeted Cancer Therapy.

Kruspe S, Giangrande PH.

Methods Mol Biol. 2017;1632:175-186. doi: 10.1007/978-1-4939-7138-1_11.

PMID:
28730439
13.

Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.

Giangrande PLF, Peyvandi F, O'Mahony B, Behr-Gross ME, Hilger A, Schramm W, Mannucci PM.

Haemophilia. 2017 May;23(3):370-375. doi: 10.1111/hae.13211. Epub 2017 Apr 12.

14.

Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline.

Hanley J, McKernan A, Creagh MD, Classey S, McLaughlin P, Goddard N, Briggs PJ, Frostick S, Giangrande P, Wilde J, Thachil J, Chowdary P; Musculoskeletal Working Party of the UKHCDO.

Haemophilia. 2017 Jul;23(4):511-520. doi: 10.1111/hae.13201. Epub 2017 Mar 30. Review. No abstract available.

PMID:
28370924
15.

Aptamers in Bordeaux, 24-25 June 2016.

Toulmé JJ, Giangrande PH, Mayer G, Suess B, Ducongé F, Sullenger B, de Franciscis V, Darfeuille F, Peyrin E.

Pharmaceuticals (Basel). 2017 Jan 20;10(1). pii: E14. doi: 10.3390/ph10010014.

16.

Making economic evaluations more helpful for treatment choices in haemophilia.

Drummond M, Houwing N, Slothuus U, Giangrande P.

Haemophilia. 2017 Mar;23(2):e58-e66. doi: 10.1111/hae.13173. Epub 2017 Jan 22. Review.

PMID:
28111847
17.

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.

Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J; Pathfinder™2 Investigators.

Thromb Haemost. 2017 Jan 26;117(2):252-261. doi: 10.1160/TH16-06-0444. Epub 2016 Dec 1. Erratum in: Thromb Haemost. 2017 Jun;117(6):1163.

PMID:
27904904
18.

DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.

Huertas-Martínez J, Court F, Rello-Varona S, Herrero-Martín D, Almacellas-Rabaiget O, Sáinz-Jaspeado M, Garcia-Monclús S, Lagares-Tena L, Buj R, Hontecillas-Prieto L, Sastre A, Azorin D, Sanjuan X, López-Alemany R, Moran S, Roma J, Gallego S, Mora J, García Del Muro X, Giangrande PH, Peinado MA, Alonso J, de Alava E, Monk D, Esteller M, Tirado OM.

Cancer Lett. 2017 Feb 1;386:196-207. doi: 10.1016/j.canlet.2016.11.020. Epub 2016 Nov 25.

PMID:
27894957
19.

Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.

Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz A, Mancuso ME, Serban M, Tsay W, Mahlangu JN.

Haemophilia. 2017 Jan;23(1):67-76. doi: 10.1111/hae.13041. Epub 2016 Aug 1.

PMID:
27480487
20.

The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.

Berntorp E, Hart D, Mancuso ME, d'Oiron R, Perry D, O'Mahony B, Kaczmarek R, Crato M, Pasi J, Miners A, Carlsson KS, Kitchen S, Boehlen F, Giangrande P, Cebura E, Uitslager N, Osooli M, Janeckova D, Haldon R, Rivolta GF.

Eur J Haematol. 2016 Jul;97 Suppl 83:3-18. doi: 10.1111/ejh.12760. Erratum in: Eur J Haematol. 2016 Dec;97(6):594.

PMID:
27272000
21.

The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy.

Giangrande P.

Semin Thromb Hemost. 2016 Jul;42(5):513-7. doi: 10.1055/s-0036-1579637. Epub 2016 May 5. Review.

PMID:
27148842
22.

Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.

Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E, Esposito CL, Quintavalle C, Giangrande PH, de Franciscis V, Condorelli G.

Mol Ther Nucleic Acids. 2016 Mar 8;5:e289. doi: 10.1038/mtna.2016.5.

23.

Structural computational modeling of RNA aptamers.

Xu X, Dickey DD, Chen SJ, Giangrande PH.

Methods. 2016 Jul 1;103:175-9. doi: 10.1016/j.ymeth.2016.03.004. Epub 2016 Mar 10.

24.

In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs.

Urak KT, Shore S, Rockey WM, Chen SJ, McCaffrey AP, Giangrande PH.

Methods. 2016 Jul 1;103:167-74. doi: 10.1016/j.ymeth.2016.03.003. Epub 2016 Mar 10.

25.

AFBI assay - Aptamer Fluorescence Binding and Internalization assay for cultured adherent cells.

Thiel WH, Giangrande PH.

Methods. 2016 Jul 1;103:180-7. doi: 10.1016/j.ymeth.2016.03.005. Epub 2016 Mar 10.

26.

Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.

Thiel WH, Esposito CL, Dickey DD, Dassie JP, Long ME, Adam J, Streeter J, Schickling B, Takapoo M, Flenker KS, Klesney-Tait J, Franciscis Vd, Miller FJ Jr, Giangrande PH.

Mol Ther. 2016 Apr;24(4):779-87. doi: 10.1038/mt.2015.235. Epub 2016 Jan 6.

27.

Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells.

Dickey DD, Giangrande PH.

Methods. 2016 Mar 15;97:94-103. doi: 10.1016/j.ymeth.2015.11.020. Epub 2015 Nov 26. Review.

28.

Analyzing HT-SELEX data with the Galaxy Project tools--A web based bioinformatics platform for biomedical research.

Thiel WH, Giangrande PH.

Methods. 2016 Mar 15;97:3-10. doi: 10.1016/j.ymeth.2015.10.008. Epub 2015 Oct 23.

29.

Method for Confirming Cytoplasmic Delivery of RNA Aptamers.

Dickey DD, Thomas GS, Dassie JP, Giangrande PH.

Methods Mol Biol. 2016;1364:209-17. doi: 10.1007/978-1-4939-3112-5_17.

30.

Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.

Santagostino E, Escobar M, Ozelo M, Solimeno L, Arkhammar P, Lee HY, Rosu G, Giangrande P.

Blood Rev. 2015 Jun;29 Suppl 1:S9-18. doi: 10.1016/S0268-960X(15)30003-5. Review.

PMID:
26073369
31.

Arresting the colonial destiny of metastatic seeds with DNA aptamers.

Condorelli G, Giangrande PH, de Franciscis V.

Mol Ther. 2015 Jun;23(6):982-984. doi: 10.1038/mt.2015.85. No abstract available.

32.

Research in haemophilia B--approaching the request for high evidence levels in a rare disease.

Berger K, Schopohl D, Hilger A, Behr Gross ME, Giangrande P, Peyvandi F, Seitz R, Schramm W.

Haemophilia. 2015 Jan;21(1):4-20. doi: 10.1111/hae.12603. Epub 2014 Dec 11. Review.

PMID:
25495927
33.

Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.

Thiel WH, Thiel KW, Flenker KS, Bair T, Dupuy AJ, McNamara JO 2nd, Miller FJ, Giangrande PH.

Methods Mol Biol. 2015;1218:187-99. doi: 10.1007/978-1-4939-1538-5_11.

34.

Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.

Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA, Chen Y, Hernandez FJ, Liu XY, Wilson ME, Allen LA, Vaena DA, Meyerholz DK, Giangrande PH.

Mol Ther. 2014 Nov;22(11):1910-22. doi: 10.1038/mt.2014.117. Epub 2014 Jun 23.

35.

Uncovered needs in the management of inherited bleeding disorders in Italy.

Arcieri R, Molinari AC, Farace S, Mazza G, Garnero A, Calizzani G, Giordano P, Oliovecchio E, Mantovani L, Manzoli L, Giangrande P.

Blood Transfus. 2014 Apr;12 Suppl 3:s563-6. doi: 10.2450/2014.0036-14s. Review. No abstract available.

36.

The European standards of Haemophilia Centres.

Giangrande P, Calizzani G, Menichini I, Candura F, Mannucci PM, Makris M.

Blood Transfus. 2014 Apr;12 Suppl 3:s525-30. doi: 10.2450/2014.0056-14s.

37.

The methodology for defining the European standards for the certification of Haemophilia Centres in Europe.

Candura F, Menichini I, Calizzani G, Giangrande P, Mannucci PM, Makris M.

Blood Transfus. 2014 Apr;12 Suppl 3:s519-24. doi: 10.2450/2014.0046-14s.

38.

Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.

Giangrande P, Seitz R, Behr-Gross ME, Berger K, Hilger A, Klein H, Schramm W, Mannucci PM.

Haemophilia. 2014 May;20(3):322-5. doi: 10.1111/hae.12440.

PMID:
24731129
39.

Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

Esposito CL, Cerchia L, Catuogno S, De Vita G, Dassie JP, Santamaria G, Swiderski P, Condorelli G, Giangrande PH, de Franciscis V.

Mol Ther. 2014 Jun;22(6):1151-1163. doi: 10.1038/mt.2014.5. Epub 2014 Jan 20.

40.

Present and future challenges in the treatment of haemophilia: the patient's perspective.

Arcieri R, Molinari AC, Farace S, Mazza G, Garnero A, Calizzani G, Giordano P, Oliovecchio E, Mantovani L, Manzoli L, Giangrande P.

Blood Transfus. 2013 Sep;11 Suppl 4:s82-5. doi: 10.2450/2013.013s. Review. No abstract available.

41.

Current progress on aptamer-targeted oligonucleotide therapeutics.

Dassie JP, Giangrande PH.

Ther Deliv. 2013 Dec;4(12):1527-46. doi: 10.4155/tde.13.118. Review.

42.

Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells.

Gourronc FA, Rockey WM, Thiel WH, Giangrande PH, Klingelhutz AJ.

Virology. 2013 Nov;446(1-2):325-33. doi: 10.1016/j.virol.2013.08.015. Epub 2013 Sep 8.

43.

Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.

Hernandez LI, Flenker KS, Hernandez FJ, Klingelhutz AJ, McNamara JO 2nd, Giangrande PH.

Pharmaceuticals (Basel). 2013 Mar 14;6(3):295-319.

44.

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.

Ljung R, Karim FA, Saxena K, Suzuki T, Arkhammar P, Rosholm A, Giangrande P; Pioneer™1 Investigators.

J Thromb Haemost. 2013 Jul;11(7):1260-8. doi: 10.1111/jth.12237.

45.

Haemophilia care in Europe - a survey of 35 countries.

O'Mahony B, Noone D, Giangrande PL, Prihodova L.

Haemophilia. 2013 Jul;19(4):e239-47. doi: 10.1111/hae.12125. Epub 2013 Apr 4.

PMID:
23557438
46.

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PH, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay J; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

Hum Mol Genet. 2013 May 1;22(9):1903-10. doi: 10.1093/hmg/ddt033. Epub 2013 Jan 30.

47.

Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection.

Thiel WH, Bair T, Peek AS, Liu X, Dassie J, Stockdale KR, Behlke MA, Miller FJ Jr, Giangrande PH.

PLoS One. 2012;7(9):e43836. doi: 10.1371/journal.pone.0043836. Epub 2012 Sep 4.

48.

Difficult clinical challenges in haemophilia: international experiential perspectives.

Forsyth AL, Giangrande P, Hay CR, Kenet G, Kessler CM, Knöbl PN, Llinás A, Santagostino E, Young G.

Haemophilia. 2012 Jul;18 Suppl 5:39-45. doi: 10.1111/j.1365-2516.2012.02887.x.

PMID:
22757683
49.

Musculoskeletal problems in persons with inhibitors: how do we treat?

Caviglia H, Narayan P, Forsyth A, Giangrande P, Gilbert M, Goddard N, Mulder K, Rahim S.

Haemophilia. 2012 Jul;18 Suppl 4:54-60. doi: 10.1111/j.1365-2516.2012.02874.x. Review.

PMID:
22726084
50.

RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB.

Huang YZ, Hernandez FJ, Gu B, Stockdale KR, Nanapaneni K, Scheetz TE, Behlke MA, Peek AS, Bair T, Giangrande PH, McNamara JO 2nd.

Mol Pharmacol. 2012 Oct;82(4):623-35. Epub 2012 Jun 29.

Supplemental Content

Loading ...
Support Center